First Merchants Corp’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$398K Sell
16,517
-400
-2% -$10.5K 0.01% 280
2026
Q1
$475K Sell
16,917
-4,100
-20% -$109K 0.02% 262
2025
Q4
$523K Buy
21,017
+2,684
+15% +$67.7K 0.02% 256
2025
Q3
$467K Sell
18,333
-1,435
-7% -$35.4K 0.02% 274
2025
Q2
$479K Sell
19,768
-11,116
-36% -$259K 0.02% 270
2025
Q1
$783K Buy
30,884
+5,548
+22% +$145K 0.03% 234
2024
Q4
$672K Buy
25,336
+1,691
+7% +$45.9K 0.03% 262
2024
Q3
$684K Buy
23,645
+865
+4% +$25.2K 0.03% 262
2024
Q2
$637K Sell
22,780
-361
-2% -$9.94K 0.03% 259
2024
Q1
$642K Sell
23,141
-16,406
-41% -$455K 0.05% 165
2023
Q4
$1.14M Sell
39,547
-122,715
-76% -$3.71M 0.09% 144
2023
Q3
$5.38M Sell
162,262
-39,785
-20% -$1.41M 0.48% 72
2023
Q2
$7.41M Sell
202,047
-39
-0% -$1.52K 0.63% 53
2023
Q1
$8.24M Sell
202,086
-10,042
-5% -$434K 0.73% 43
2022
Q4
$10.9M Buy
212,128
+16,897
+9% +$810K 1% 29
2022
Q3
$8.54M Buy
195,231
+4,609
+2% +$224K 0.86% 34
2022
Q2
$9.99M Sell
190,622
-7,550
-4% -$385K 0.99% 30
2022
Q1
$10.3M Sell
198,172
-3,665
-2% -$190K 0.84% 33
2021
Q4
$11.9M Sell
201,837
-14,190
-7% -$703K 0.92% 29
2021
Q3
$9.29M Sell
216,027
-388
-0.2% -$17.2K 0.59% 37
2021
Q2
$8.47M Buy
216,415
+1,264
+0.6% +$49.2K 0.55% 42
2021
Q1
$7.79M Buy
215,151
+10,088
+5% +$358K 0.52% 47
2020
Q4
$7.55M Sell
205,063
-3,528
-2% -$129K 0.52% 45
2020
Q3
$7.26M Buy
208,591
+22,129
+12% +$776K 0.55% 38
2020
Q2
$5.79M Buy
186,462
+6,446
+4% +$219K 0.49% 49
2020
Q1
$5.57M Buy
180,016
+3,349
+2% +$114K 0.72% 43
2019
Q4
$6.57M Sell
176,667
-5,848
-3% -$208K 0.67% 46
2019
Q3
$6.22M Buy
182,515
+67,118
+58% +$2.44M 0.66% 43
2019
Q2
$4.74M Buy
115,397
+1,796
+2% +$71.3K 0.75% 45
2019
Q1
$4.58M Buy
113,601
+6,551
+6% +$262K 0.74% 49
2018
Q4
$4.43M Buy
107,050
+438
+0.4% +$18.2K 0.85% 37
2018
Q3
$4.46M Sell
106,612
-800
-0.7% -$30.8K 0.73% 49
2018
Q2
$3.7M Buy
107,412
+6,455
+6% +$221K 0.64% 56
2018
Q1
$3.4M Buy
100,957
+901
+0.9% +$31K 0.57% 58
2017
Q4
$3.44M Buy
100,056
+607
+0.6% +$20.7K 0.59% 59
2017
Q3
$3.37M Buy
99,449
+16,591
+20% +$533K 0.58% 62
2017
Q2
$2.64M Buy
82,858
+5,761
+7% +$182K 0.73% 51
2017
Q1
$2.5M Buy
77,097
+2,823
+4% +$89K 0.7% 53
2016
Q4
$2.29M Buy
74,274
+8,853
+14% +$270K 0.68% 51
2016
Q3
$2.1M Sell
65,421
-1,531
-2% -$51.2K 0.67% 52
2016
Q2
$2.24M Buy
66,952
+8,531
+15% +$272K 0.74% 49
2016
Q1
$1.64M Buy
58,421
+8,969
+18% +$256K 0.58% 63
2015
Q4
$1.51M Buy
49,452
+3,765
+8% +$118K 0.53% 66
2015
Q3
$1.36M Buy
45,687
+24,358
+114% +$781K 0.49% 73
2015
Q2
$678K Buy
21,329
+1,864
+10% +$60.8K 0.21% 108
2015
Q1
$643K Buy
19,465
+9,196
+90% +$292K 0.2% 109
2014
Q4
$303K Sell
10,269
-2,082
-17% -$59.7K 0.09% 127
2014
Q3
$346K Buy
12,351
+527
+4% +$14.8K 0.11% 124
2014
Q2
$333K Sell
11,824
-153
-1% -$4.36K 0.1% 126
2014
Q1
$365K Sell
11,977
-4,627
-28% -$138K 0.12% 121
2013
Q4
$483K Sell
16,604
-1,552
-9% -$45.2K 0.16% 110
2013
Q3
$494K Sell
18,156
-2,554
-12% -$69.5K 0.17% 107
2013
Q2
$550K Buy
+20,710
New +$572K 0.2% 103

Other funds holding PFE

First Merchants Corp's PFE Position: Q2 2026 in Review

First Merchants Corp reduced its Pfizer (PFE) stake by 2.4% in Q2 2026, selling an estimated $10.5K and leaving 16,517 shares worth $398K. The position accounts for 0.01% of the portfolio, ranked #280.

First Merchants Corp first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.9M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • First Merchants Corp held 16,517 shares of Pfizer worth $398K as of Q2 2026.
  • First Merchants Corp sold 400 Pfizer shares in Q2 2026, an estimated $10.5K.
  • Pfizer made up 0.01% of First Merchants Corp's portfolio in Q2 2026, its #280 holding.
  • First Merchants Corp first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • First Merchants Corp's Pfizer position peaked at $11.9M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on First Merchants Corp's 13F filing for Q2 2026, filed 15 Jul 2026.